Earnings Feed
Start Free
AGIOS PHARMACEUTICALS, INC.·4

Jun 23, 5:22 PM ET

FOUSE JACQUALYN A 4

Research Summary

AI-generated summary

Updated

AGIOS (AGIO) Director Jacqualyn Fouse Exercises Derivative, Receives RSUs

What Happened

  • Jacqualyn A. Fouse, a director of Agios Pharmaceuticals (AGIO), converted/exercised 2,816 derivative units on June 18, 2026 (reported as "M") and had a same‑day disposition of 2,816 derivative units. All of these derivative transactions show $0.00 per share.
  • On the same date she was credited with awards of restricted stock units (RSUs) totaling 17,877 RSUs: 2,927 RSUs (granted June 18, 2025) and 14,950 RSUs (granted June 18, 2026). All awards are reported at $0.00. This filing reflects exercises/conversions and grant/award activity rather than an open‑market purchase or sale.

Key Details

  • Transaction date(s): June 18, 2026. Report filed: June 23, 2026.
  • Transactions reported:
    • M: Exercise/conversion — 2,816 shares acquired @ $0.00
    • M: Exercise/conversion — 2,816 shares disposed @ $0.00 (same day)
    • A: RSU award — 2,927 shares @ $0.00 (acquired)
    • A: RSU award — 14,950 shares @ $0.00 (acquired)
  • Vesting/delivery notes:
    • The 2,927 RSUs were granted 6/18/2025 and vest in full on 6/18/2026; vested shares to be delivered within three business days after vesting. (F2)
    • The 14,950 RSUs were granted 6/18/2026 and vest in full on 6/18/2027; delivery within three business days after vesting. (F3)
    • Options referenced in the filing were granted 6/18/2026 and vest 100% on 6/18/2027. (F4)
    • Each RSU represents a contingent right to one common share. (F1)
  • Shares owned after transaction: Not specified in this Form 4.
  • Filing timeliness: The Form 4 was filed June 23, 2026 for a June 18 transaction. Form 4s are generally due within two business days, so this filing appears to have been filed several days after the transaction.

Context

  • "M" (exercise/conversion of derivative) entries indicate conversion/exercise activity (e.g., RSU conversion or option exercise). The matching same‑day disposition of 2,816 units is reported but the Form 4 does not specify the reason (for example, tax withholding or transfer); no cash was reported as paid or received.
  • These entries are primarily awards and conversions rather than open‑market buys or sales; awards and vesting are standard compensation events for directors and do not by themselves indicate a buy/sell market signal.